SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (118 reviews)

For research use only.

Catalog No.S1077

118 publications

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 118 publications

Immunity, 2021, S1074-7613(21)00210-7

PubMed: 34115964 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):316

PubMed: 33767160 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Front Oncol, 2021, 11:657210

PubMed: 34026633 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4463

PubMed: 33923316 ( click the link to review the publication )

Biosci Rep, 2021, 41(3)BSR20192668

PubMed: 33616153 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Integr Biol (Camb), 2021, 13(6):139-152

PubMed: 33989405 ( click the link to review the publication )

Oncotarget, 2021, 12(9):878-890

PubMed: 33953842 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )
Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)E2114

PubMed: 28991210 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )
Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NHLFRVBHfW6ldHnvckBCe3OjeR?=	NYfvcZc3OjVizszN	NEf0NIg{OCCvaX6=	Ml3KSG1UV8Li	MoSzZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG=	NGHYVVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKyN\|I2OSd-Mk[yNlMzPTF:L3G+
MDA-MB-231	MnnXSpVv[3Srb36gRZN{[Xl?	Mlf2NkDPxE1?	NHztWXUzPCCq		MYDs[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>?	MoLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEC4OFgoRjJ4MUCwPFQ5RC:jPh?=
rBMSCs	NILhVFhHfW6ldHnvckBCe3OjeR?=	MUexNEDPxE1?	NFT5U3MzNjViaB?=		NUPGbpRo\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN\|g>	M3XYWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEWzNlY3Lz5{NkC1N\|I3PjxxYU6=
MG63	M4jtR2Z2dmO2aX;uJGF{e2G7	MV:xNE8zOC9\|MDFOwG0>	M2nJTFI1KGh?		NX3LfHl[e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>?	NGTE[mU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PFMyOid-MkW5PVg{OTJ:L3G+
MG63	NYfZVW1RSXCxcITvd4l{KEG\|c3H5	MnriNVAwOjBxM{Cg{txO	NU[xOZo1OjRiaB?=		MXvzbYdvcW[rY3HueIx6KGSnY4LlZZNm\CC2aHWgZZBweHSxc3nzJJJifGVib3[gUWc3OyCrbnT1Z4VlKGK7IFPkR4wz	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7OEOxNkc,OjV7OUizNVI9N2F-
HTSMCs	NY\Q[HZvTnWwY4Tpc44hSXO\|YYm=	MnrxNE4yNzFxMUCg{txO	MVuxJIg>		NUT1SWlKcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	NVnBNGN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NlE1PjRpPkK1PVIyPDZ2PD;hQi=>
MIA PaCa-2	M2jnO2Z2dmO2aX;uJGF{e2G7	NFPPcGYzOMLizszN	M3Hjb\|I1KGh?		NHvuR2hz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh	M2rlN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
MIA PaCa-2	NEjyeHdHfW6ldHnvckBCe3OjeR?=	NIL1fJMzOMLizszN	NF7ISmMzPCCq		MXTy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
BxPC-3	M3:wU2Z2dmO2aX;uJGF{e2G7	Mlj6NlDDqM7:TR?=	NGPoUGgzPCCq		NVXENlM4emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NH75NGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
AsPC-1	NXS2Sm5qTnWwY4Tpc44hSXO\|YYm=	NH7OVZgzOMLizszN	MmrhNlQhcA>?		NVXFfplDemW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NH3vRmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MIA PaCa-2	M2DxOGZ2dmO2aX;uJGF{e2G7	NFHV[pMzOMLizszN	NFrzN5YzPCCq		NHfJfmNmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJJdp\W5iY3;tZolv\WRid3n0bEBodHWlb4PlJIFv[WyxZ4O=	NEfPSYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MIA PaCa-2	M{DsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnPSoNPOjEEoN88US=>	M1nnVlIhcA>?		NHu4cpl{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	NXzHcFhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
BxPC-3	M372S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;TfndEOjEEoN88US=>	NYrVfYNFOiCq		MUXz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U>	Mn:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
AsPC-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[xNlDDqM7:TR?=	MYiyJIg>		NXLiSYp3e2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NFi3T5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
HEY	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLpWHAzOMLizszN	M3jod\|IhcA>?		MkO3d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NYrWSlkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
OVCAR-3	M3e0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKyNOKh\|ryP	M1;rPVIhcA>?		NELa[YR{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
SK-OV-3	MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzJNlDDqM7:TR?=	NXPTVlRpOiCq		NHv1eVJ{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MH7A	NXfiT29JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M37xSFI1KGh?		NVzJTHlOemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?=	NGDuO4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2Nlk3Pid-MkW4OlI6PjZ:L3G+
MH7A	MljyRZBweHSxc3nzJGF{e2G7	NELvVnozPSEQvF2=	M1u0clI1KGh?		MYPy[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms>	NH3iSHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2Nlk3Pid-MkW4OlI6PjZ:L3G+
SCC25	NGPKe4NHfW6ldHnvckBCe3OjeR?=	MmXlNlAh\|ryP	M3Puc\|I1KGh?		MlHmbY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?=	M1XVV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAxLz5{NUizOFQxODxxYU6=
HaCaT	MUfGeY5kfGmxbjDBd5NigQ>?	M4H0flUhyrWP	M{S0XVI1KGh?		NFjiR4lqdmirYnn0d{BKTk5vzsOtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>?	M4\vcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0N\|U{Lz5{NUizOFM2OzxxYU6=
HaCaT	NIrCeWNHfW6ldHnvckBCe3OjeR?=	MXq1JOK2VQ>?	M2q3SVI1KGh?		MUTpcohq[mm2czDJSm4u\|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	M4\qbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0N\|U{Lz5{NUizOFM2OzxxYU6=
HPAEpiCs	NXPGe\|dkTnWwY4Tpc44hSXO\|YYm=	NH32[ngyNzNxMUCg{txO	M4XkPFEhcA>?		MVvy[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	MmXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{S5NFAoRjJ3N{O0PVAxRC:jPh?=
HPAEpiCs	MnvMSpVv[3Srb36gRZN{[Xl?	MY[xM\|MwOTBizszN	M3jEdVEhcA>?		MUXpcohq[mm2czDTNXAue3SrbYXsZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wIDFCpC=>	M2jXXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{O0PVAxLz5{NUezOFkxODxxYU6=
HPAEpiCs	NGXpUWZHfW6ldHnvckBCe3OjeR?=	Ml\vNU8{NzFyIN88US=>	NGn1WYgyKGh?		M3r4S4lvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u	NVLrT5hSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
K562	NV:wSnhxTnWwY4Tpc44hSXO\|YYm=	NH;icGIyOMLizszN	NHzsb3UyyqCq	Ml;pSG1UVw>?	M3zzXYlvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	NHPEfHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4OFA1Oyd-MkW2PFQxPDN:L3G+
PANC-1	NF3QeWRHfW6ldHnvckBCe3OjeR?=	NV3qRpRYOTBizszN	NILYe4IyKGh?		MXrlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyNkc,OjV4M{KyNlI9N2F-
BxPC-3	NIPNXGxHfW6ldHnvckBCe3OjeR?=	MWOxNEDPxE1?	NETzeZMyKGh?		M3zvUIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi	NVjsO4FlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjJpPkK1OlMzOjJ{PD;hQi=>
K562	NUP6PHR3TnWwY4Tpc44hSXO\|YYm=	MXmwMlI2NTFizszN	M163[\|I1KGh?		NVnadZJve3WycILld5NmeyC{ZYP2[ZJifHKxbD3pcoR2[2WmIFiyRXgheGixc4Doc5J6dGG2aX;u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZzOUO5Nkc,OjV4MUmzPVI9N2F-
THP-1	M1y3c2Z2dmO2aX;uJGF{e2G7	MorkOUDDvU1?	NYjUUFdvOiCq		NY[wO3lFe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJJNm[3KndHnvckBw\iCLTD2x{tEhcW6mdXPl[EBjgSB{N1;IR4hwdCCybIXzJGZUVC1zwrC=	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUi2OlEoRjJ3NUm4OlYyRC:jPh?=
WB	NXPqNpR7TnWwY4Tpc44hSXO\|YYm=	M3vBbFIx6oDLzszNxsA>	MXWzNQKBkW2rbh?=		NULRN3pl\GWlcnXhd4V{KHSqZTDMVHMuKG:{IFzURU1qdmS3Y3XkJGlNNTZiYX7kJHRPTi4QsdMgdJJw\HWldHnvci=>	MnP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{C2PFIoRjJ3NUOwOlgzRC:jPh?=
RAW 264.7	M{jaOWZ2dmO2aX;uJGF{e2G7	NXT1NYJFOTEEoN88US=>	MlvkN\|DjiImvaX6=		M1OyU4lv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O\|wrC=	NF7oNWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NVM6QSd-MkW0OlE{QTl:L3G+
RAW 264.7	M3XpXWZ2dmO2aX;uJGF{e2G7	MYWxNOKh\|ryP	MUWzNQKBkW2rbh?=		NGjlSmVifHSnboXheIV{KHSqZTDl[oZm[3S\|IH;mJG9RTyCxbjDvd5Rmd2OuYYP0JJJmfHKjY4Tpc44>	M4\1OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[xN\|k6Lz5{NUS2NVM6QTxxYU6=
HaCaT	M1rmZmZ2dmO2aX;uJGF{e2G7	MmK2OFDDqM7:TR?=	NHq1UmI{NTJ2IHi=	M123RmROW09?	M1LsRZJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z	NHPxWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOVQ5PSd-MkW0N\|U1QDV:L3G+
H9c2	MnHISpVv[3Srb36gRZN{[Xl?	MoTZOVDDqM7:TdMg	NWjZNph2OTJiaB?=		NW[1cWw{emWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O=	M4f6R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkS1PFE5Lz5{NUK0OVgyQDxxYU6=
HSCs	MXXBdI9xfG:\|aYOgRZN{[Xl?	MUeyOUDPxE1?	M1n1VFI1yqCq		NVnz[lEye2mpbnnmbYNidnSueTDheJRmdnWjdHXzJHRINWmwZIXj[YQh[WO2aY\heIVlKEiVQ4OgZZBweHSxc3nz	M1LPblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xPVUxLz5{NEm2NVk2ODxxYU6=
THP-1	M4fHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlXaO\|IhcA>?	NEPmb5BFVVOR	M4HQW2lEPTB;ND63{txO	Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	M3izbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPEPYd5PzJiaB?=	MUTEUXNQ	M3XiN2lEPTB{LkhOwG0>	NYK5cphnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	NUjjVmZwTnWwY4Tpc44hSXO\|YYm=	MmTpNE0yPSEQvF2=	M{K4fVQ5KGh?	M1K0cWROW09?	MULzeZBxemW\|c3XzJGlHVi4QsTDhcoQhUVBvMUCgdJJw\HWldHnvcuKh	NUntR2g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	MWLGeY5kfGmxbjDBd5NigQ>?	MUCwMVE2KM7:TR?=	MVO0PEBp	M1XFXGROW09?	MlnzbY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u	MoS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	M2TXNWZ2dmO2aX;uJGF{e2G7	M3q5ZVExKM7:TR?=	M3:1OlMvPSCq	MVXEUXNQ	NFvXblRjdG:la4OgSWJQXiCJUDygZpV1KG6xdDDWV3YhTyCvZXTpZZRm\CCnboTyfUBqdnSxIHj1cYFvKE2GRFPz	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzNUC4O{c,OjR6MUWwPFc9N2F-
macrophages	NHPofotHfW6ldHnvckBCe3OjeR?=	NH\CTHIy6oDLzszN	NIS4ZXk1NjYkgJno		MULjc41xdGW2ZXz5JIlvcGmkaYTzJG1VNUmLST3pcoR2[2WmIHHjeIl3[XSrb36gc4YhVkZvzsrC	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyOE[zN{c,OjR6MEi2N\|M9N2F-
PDL	MmHzSpVv[3Srb36gRZN{[Xl?	NXT4W3ZGOjEEoN88UeKh	MmH5N\|AhdWmw	MoXLSG1UVw>?	MmTQd4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgeIVve2muZTDmc5Jk\S2vZXTpZZRm\CCETWCtNkBmgHC{ZYPzbY9v	NXK2WpNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlExQDFpPkK0OVYyODhzPD;hQi=>
AGS	M4DEcGZ2dmO2aX;uJGF{e2G7	NGexU4E2KM7:TR?=	MUWzNEBucW5?		MWjzeZBxemW\|c3XzxsAyNWmwZIXj[YQh[2G\|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	M3LjSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUS3PFc5Lz5{NEW0O\|g4QDxxYU6=
H520	MnTtSpVv[3Srb36gRZN{[Xl?	NFvpR4kyOMLiwsXN	NXTu[opTOSCq	NWGwbmFbTE2VTx?=	MXjk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H1703	M{nkbGZ2dmO2aX;uJGF{e2G7	MmT6NVDDqML3TR?=	NHj2fYEyKGh?	M2XOOWROW09?	MVrk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H520	NYrEVWcyTnWwY4Tpc44hSXO\|YYm=	Mme0NVDDqML3TR?=	MUexNkBp	M1rtVmROW09?	MYfpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC\|dHHibYxqfHl?	NIHVcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	MXnGeY5kfGmxbjDBd5NigQ>?	MUixNOKhyrWP	NXXhZ3ZoOTJiaB?=	MlfOSG1UVw>?	MmjobY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7	NGLuU\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H520	NYXYeIQ2TnWwY4Tpc44hSXO\|YYm=	MkLtNVDDqML3TR?=	NXfjR\|VTPiCq	MoThSG1UVw>?	NULJXIVCe2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l	NVW5PGp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H1703	NFHqXHZHfW6ldHnvckBCe3OjeR?=	NHHHOIkyOMLiwsXN	NH;2cWg3KGh?	M16xW2ROW09?	Mn\Vd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	M3HSWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
MC3T3-E1	NYe5V4puTnWwY4Tpc44hSXO\|YYm=	MXqwMlMwOy9\|MDFOwG0>	M{O4elEhcA>?		MY\heJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25iaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	MknPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEK2PVYoRjJ2NUCyOlk3RC:jPh?=
MC3T3-E1	M3vRbGZ2dmO2aX;uJGF{e2G7	NEjlZ\|M{OCEQvF2=	MYWxJIg>		NVnycoZX[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NXi1dmVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFI3QTZpPkK0OVAzPjl4PD;hQi=>
HUVECs	NF;xOnhHfW6ldHnvckBCe3OjeR?=	M2HuWVExyqEEtV2=	M1fBNVEhcA>?		MkfVbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6N{m2OEc,OjR2OEe5OlQ9N2F-
AGS	MXnGeY5kfGmxbjDBd5NigQ>?	NYfvfG5MOTEEoNM1US=>	NF3USlk{OMLibXnu		M4i2SYlvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	NGfZSGRHfW6ldHnvckBCe3OjeR?=	NFrZfo4yOMLiwsXN	MYWzNOKhdWmw		MWnpcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	NWfkV2tNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k3QDFpPkK0OFc6PjhzPD;hQi=>
AGS	M4HC[WZ2dmO2aX;uJGF{e2G7	Mm\jNVDDqML3TR?=	MWWzNOKhdWmw		MUfheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	MYLGeY5kfGmxbjDBd5NigQ>?	MUOxNOKhyrWP	MUizNOKhdWmw		NIfmcmdifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	M2DJXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
AGS	MnTLSpVv[3Srb36gRZN{[Xl?	MkXrNVDDqML3TR?=	NW\BdFFDOzEEoH3pci=>		NF\CV2F{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	MXTGeY5kfGmxbjDBd5NigQ>?	NXHR[o9lOTEEoNM1US=>	M1KxbVMxyqCvaX6=		NVK1W5I{e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36=	NHHDN3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3PVY5OSd-MkS0O\|k3QDF:L3G+
DCs	M1nFfmZ2dmO2aX;uJGF{e2G7	NGjjOGgzOMLizszN	NF3COY8yyqCq		NH7wWlhl\WO{ZXHz[ZMhUUxvMUKgdJJw\HWldHnvci=>	NF3sVYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzOFY{Pid-MkS0N\|Q3OzZ:L3G+
HUVEC	NHq3TW9HfW6ldHnvckBCe3OjeR?=	M3rHSFIxKM7:bdMg	MnXqOUBp	MnrwSG1UVw>?	NGHYXJdz\WS3Y3XzJIN6fG:taX7lJIV5eHKnc4Ppc44hdGW4ZXzzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy	MnjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEmwOlIoRjJ2MUi5NFYzRC:jPh?=
A 549	NV\WTIROTnWwY4Tpc44hSXO\|YYm=	Ml\oOVAh\|ryP	Mn;DNUBp		M{TpdoRm[3KnYYPld{B1cGVibHX2[Ywhd2ZiSVytPOKh	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5OU[4PEc,OjRzN{m2PFg9N2F-
H520	MmnuSpVv[3Srb36gRZN{[Xl?	NF7VXoc2NzFyIN88US=>	MmHZNUBp	NYjB[nRwTE2VTx?=	MXvk[YNz\WG\|ZYOgUXNJOiCycn;0[YlvKGG\|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?=	NUTvdWN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H1703	NIO0RoZHfW6ldHnvckBCe3OjeR?=	NUe3RpNMPS9zMDFOwG0>	MYCxJIg>	MmPQSG1UVw>?	M{PISYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	M3yxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO4PVA{Lz5{NEGzPFkxOzxxYU6=
H520	Mni4SpVv[3Srb36gRZN{[Xl?	NV[0fIJZOTEEoNM1US=>	M2XNSFEzKGh?	MUfEUXNQ	NWnHXHdo\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN?	MnXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i5NFMoRjJ2MUO4PVA{RC:jPh?=
H1703	MmO2SpVv[3Srb36gRZN{[Xl?	NXe4NXA6OTEEoNM1US=>	NULsZodVOTJiaB?=	M1v4NGROW09?	NFjKblFl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
MCF-7	NYjFem5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITkeFYyOMLizszN	NGDZbokzPMLiaB?=		M1X4OIlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg>	NX:2N4JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlg5PTNpPkK0NVI5QDV\|PD;hQi=>
HPAEpiCs	Ml3qSpVv[3Srb36gRZN{[Xl?	MljtNE4yNzFxMUCg{txO	NEL5O3UyKGh?		NWfCfZdXcW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ3BNSTMEoIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbh?=	M4\SeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NVU5Lz5{NEC2PVE2QDxxYU6=
podocytes	M2\rWWZ2dmO2aX;uJGF{e2G7	MUKxNOKh\|ryP	Mk\XNUBp		MWfpcohq[mm2czDUS2bPujFvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFugZY5lKEW{a{GvNuKh	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB\|NkKxNkc,OjRyM{[yNVI9N2F-
MCF-7	M3v3W2Z2dmO2aX;uJGF{e2G7	NUHKZWk1OTEEoN88US=>	NVnIUGJwOSCq	NWPrPW9qTE2VTx?=	M17Dc5Jm\HWlZYOgeIhmKFeDLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQheDN6IF3BVGs>	NX[3[XFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVkxQTBpPkK0NFE6ODlyPD;hQi=>
MCF-7	NXT4eJZ4TnWwY4Tpc44hSXO\|YYm=	MVSxNOKh\|ryP	MmrqNlQhcA>?	MlvUSG1UVw>?	MnjibY5kemWjc3XzJJRp\SCZQT3pcoR2[2WmIHHwc5B1d3Orcx?=	M2noUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NFkxLz5{NECxPVA6ODxxYU6=
HAPI	MnrrSpVv[3Srb36gRZN{[Xl?	M3jXdVExNzJyL{SwxsDPxE1?	M4HSNVEhcA>?		MmK2bY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB\|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25?	MoLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkmxNlAoRjJ\|OU[5NVIxRC:jPh?=
HAPI	M4ruZ2Z2dmO2aX;uJGF{e2G7	MXmyNOKh\|ryPwrC=	MXGxJIg>	NGj2bm5FVVOR	NWfrb\|J{[XS2ZX71ZZRmeyCWQ1TEMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCrTl;TJIFv\CCycn;keYN1cW:w	NFj3RY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2PVEzOCd-MkO5OlkyOjB:L3G+
HepG2	NHf1ZWpHfW6ldHnvckBCe3OjeR?=	MUWzOVAhdk1?	NFnkPZAzPCCq		NEjkcFRqdmirYnn0d{B1cGViZHXneYVtcW5vaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFu=	M{XqZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUOzNVk5Lz5{M{mzN\|E6QDxxYU6=
AGS	M3XD[mZ2dmO2aX;uJGF{e2G7	MUmxNOKh\|ryP	M4rrTFMxKG2rbh?=		NXuxfZJRcW6qaXLpeJMh[2G\|cHHz[U0{KGGldHn2ZZRqd25iYX7kJIlvcGmkaYTpc44hd2ZiRWLL	NX;DdFRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVA6QTRpPkKzPFUxQTl2PD;hQi=>
HepG2	NGL2XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TWVFAuPTBizszN	MVK0PEBp		NF;hVmZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
BEL7404	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PZRVAuPTBizszN	MXK0PEBp		NUHjfJNocW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MEe1NFgoRjJ\|OEC3OVA5RC:jPh?=
HL7702	NXrSSHBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHJSnBsOC13MDFOwG0>	NYPxc2V3PDhiaB?=		MXrpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
HepG2	MnjoSpVv[3Srb36gRZN{[Xl?	Ml;tNE02OCEQvF2=	M13nN\|I1KGh?		MVHpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKHB\|ODDkc5dve3S{ZXHtJJBzd3SnaX7zJG1CWEuDUFuyMEBCXEZ{LDDNV2syKGGwZDDIV3AzPyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NFjtboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwO\|UxQCd-MkO4NFc2ODh:L3G+
BEAS-2B	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\hTlQ2OTBizszN	MorTN\|AhdWmw		NVrPeVZ[emW4ZYLz[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgTGNK	NEX1dWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
BEAS-2B	M1\nbWN6fG:2b4jpeJkhSXO\|YYm=	M{fMVlExKM7:TR?=	NYrobZVXOzBibXnu		M2TZfYlvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25?	Ml\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
BEAS-2B	MXHGeY5kfGmxbjDBd5NigQ>?	MVexNEDPxE1?	NUnodW9sOzBibXnu		NGXzbXhl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{	NIjBcFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
H9c2	MWPGeY5kfGmxbjDBd5NigQ>?	NF:xSXIxNjBzL{CuNU8yKM7:TR?=	M{PNflEhcA>?		M3TvNYF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjygcXJPSSCuZY\lcJMtKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd5NEK1Nkc,OjN5N{SyOVI9N2F-
H9c2	MX3GeY5kfGmxbjDBd5NigQ>?	NGGzXWMyKM7:TR?=	MnLQNUBp		M{fPZ5Jm\HWlZYOgWG5HNc7zIHTpdoVkfGy7IIP0bY12dGG2ZXSgdFM5KE2DUFugdIhwe3Cqb4L5cIF1cW:w	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd5NEK1Nkc,OjN5N{SyOVI9N2F-
U937	NWCwPXNZTnWwY4Tpc44hSXO\|YYm=	MnfENVDDqM7:TdMg	MmGzNUBp		MWPhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	M3vsPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3N\|g4Lz5{M{ewO\|M5PzxxYU6=
U937	Ml6ySpVv[3Srb36gRZN{[Xl?	Ml62NVDDqM7:TdMg	MnnRNUBp		MWThZpJw\2G2ZYOgZ4Fn\mWrbnWtbY5lfWOnZDDNT3AuOSCmb4fuMZJm\3WuYYTpc44h[W6mIGDQNmFk\|rFidYCtdoVofWyjdHnvci=>	NGPv[XY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|M5Pyd-MkO3NFc{QDd:L3G+
U937	MVnGeY5kfGmxbjDBd5NigQ>?	MXWxNOKh\|ryPwrC=	M1SxW\|EhcA>?		NFX2dpp{fXCycnXzd4V{KGNvSoXuJIFv\CCFUlXCJJBpd3OyaH;yfYxifGmxbjDpckBk[W[oZXnu[U11emWjdHXkJINmdGy\|wrC=	Mm\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEezPFcoRjJ\|N{C3N\|g4RC:jPh?=
A549	MknESpVv[3Srb36gRZN{[Xl?	M{jvPVAvOy9\|L{OwJO69VQ>?	NYXKO2xtOSCq		NF:0T4J{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR\|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=>	NVvubWxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
A549	M333W2Z2dmO2aX;uJGF{e2G7	M3LXXlExyqEQvF5CpC=>	MVqwMVMxKG2rbh?=		M3XTc4lvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIIC0Nk9xPDRiTVHQT{BidmRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v	MkfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
A549	M3js[2Z2dmO2aX;uJGF{e2G7	NFnmfmkyOMLizszNxsA>	NULyU4szOSCq		MV7pcohq[mm2czDBWHDPu1NiaX7keYNm\CCQRj5OvmIheDZ3IIP1ZpVvcXRicHjvd5Bpd3K7bHH0bY9vKGGwZDDOSk3PwkJicILvcY91\XJiYXP0bZZqfHl?	NY\XNHBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
A549	NF7pVW1HfW6ldHnvckBCe3OjeR?=	NFKzPZIyOMLizszNxsA>	M1HFNFEhcA>?		NF;nRlNz\WS3Y3XzJGFVWM7\|Uz3zeIlufWyjdHXkJINRVEF{IIDoc5NxcG:{eXzheIlwdsLi	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6ME[3OEc,OjN4OEC2O\|Q9N2F-
A549	NFXEVGhHfW6ldHnvckBCe3OjeR?=	NWPBR2F1OTEEoN88UeKh	NHLScVEyKGh?		MVjy[YR2[2W\|IFHUVO6{Wy2nbnjhcoNm\CCnbor5cYF1cWNiYXP0bZZqfHlib3[gZ3BNSTMEoB?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6ME[3OEc,OjN4OEC2O\|Q9N2F-
PC12	MWnGeY5kfGmxbjDBd5NigQ>?	NYX3cIRsOTBxMkCvOFAh\|ryP	NVLzTWVuOcLiaB?=		NHvuRYtqdmirYnn0d{BLVktiYX7kJJA{QA>?	NGP4N3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4OFM2Pyd-MkO1PFQ{PTd:L3G+
HK-2	M1f5WGFxd3C2b4Ppd{BCe3OjeR?=	MVqyNOKh\|ryP	NInHR3czPCCq		MoDhbY5pcWKrdIOgSXJMKGGwZDDwN\|hOSVCN	M2jhWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSzNVUyLz5{M{W0N\|E2OTxxYU6=
H9c2	M{S1fGZ2dmO2aX;uJGF{e2G7	M4\od\|HDqM7:TR?=	MWWxJIg>		NYnkO5NoemWmdXPld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCvUl7BJIxmfmWuczDhcoQheHKxbX;0[ZIh[WO2aY\peJk>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3M{[5PUc,OjN\|NUO2PVk9N2F-
H9c2	M{G0WGZ2dmO2aX;uJGF{e2G7	NFvue4kyyqEQvF2=	MnXYNUBp		MV\y[YR2[2W\|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5	NFnwN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O1N\|Y6QSd-MkOzOVM3QTl:L3G+
H1650	MlTPSpVv[3Srb36gRZN{[Xl?	MY[xNOKh\|ryPwrC=	MUixJIg>	NYTOV3hUTE2VTx?=	NI\0NmJl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ{OE[5Okc,OjN{Mki2PVY9N2F-
H1703	NV;M[pBtTnWwY4Tpc44hSXO\|YYm=	M{PoRVExyqEQvF5CpC=>	M3jmc\|EhcA>?	MVLEUXNQ	MV;k[YNz\WG\|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{	NY\4V5pwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1650	M{n4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:1VGIyOMLizszNxsA>	NFr2dpIyKGh?	NXzjTZZWTE2VTx?=	MoTI[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	NFj2XJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFY6Pid-MkOyNlg3QTZ:L3G+
H1703	NVPKXlNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPaNVDDqM7:TdMg	NW[xS4pWOSCq	NEi3SY1FVVOR	M2fGUoVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl?	NVjSN\|F7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
medulloblastoma cells	NYC3dJpYSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M17EUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibXXkeYxtd2KuYYP0c41iKGOnbHzzJIhiemKxcnnu[{Bp\XSncn;6fYdwfXNicITjbFEh\2WwZTDifUBOXFRiYYPzZZktKEWFNUCgQUA{NjByNjFOwG0v	MlS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUe2N\|EoRjF5NEG3OlMyRC:jPh?=
neural precursor cells	NHrRU\|hCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				M1vsemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2VibnX1doFtKHC{ZXP1dpNweiClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVAhRSB6LkC2N{DPxE1w	NHPuT4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxO\|Y{OSd-MUe0NVc3OzF:L3G+
RAW264.7	MVPBcpRqcW6obHHtcYF1d3K7IHHzd4F6		NFfyUW8yOCCvaX7z		NInZZ2RCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiCrbnP1ZoF1\WRiZn;yJFExKG2rboOgdJJqd3JidH:gUHBUNWOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAyQCCqcoOgZpkhT3KrZYPzJI1mfGixZDygTWM2OCB;IEG2JO69VS5?	Mlr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{G3PVgoRjJ{OEOxO\|k5RC:jPh?=
BL21(DE3)	M3[0e2Z2dmO2aX;uJIF{e2G7		MWG2NEBucW6\|		M2fjNWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDIbZM3NXSjZ3fl[EBDWkR2IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgbIl{fG:wZTDIOEBx\XC2aXTlJIF{KHO3YoP0doF1\SCjZoTldkA3OCCvaX7zJIJ6KEGucHjhV4Nz\WWwIHHzd4F6NCCLQ{WwJF0hOy52IN88UU4>	M33pSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUm1O\|I{Lz5{OEG5OVczOzxxYU6=
RAW264.7	Mn;lSpVv[3Srb36gZZN{[Xl?				Ml3SVJJwfGWldHnvckBi\2GrboP0JGJi[2mubIXzJIFvfGi{YXPpd{Bxem:2ZXP0bZZmKGGwdHnn[Y4h[W6mIHzleIhidCC2b4jpck1lcXCqdHjldoliKHSxeHnuJINpcW2ncnnjJJBzd3SnaX6gcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6KGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5	M2DwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEi1OVA1Lz5zN{S4OVUxPDxxYU6=
A673	MmqzdWhVWyCjc4PhfS=>				NFTJcGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NU\xWpRveUiWUzDhd5NigQ>?				NXO5dJBpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NFT4eZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MmrZdWhVWyCjc4PhfS=>				MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NVjWfGdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NGrYTlRyUFSVIHHzd4F6				M2XZRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MoPXdWhVWyCjc4PhfS=>				MmPVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM>	M{fMW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NVKzdXczeUiWUzDhd5NigQ>?				NGfkSYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	M1u0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NH7uZYhyUFSVIHHzd4F6				M{nneJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NFHwRoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M4r6V5FJXFNiYYPzZZk>				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	NFXrXoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NVvtfIszeUiWUzDhd5NigQ>?				MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M3fTcJFJXFNiYYPzZZk>				M1rCT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	NVHTXI5PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MWTxTHRUKGG\|c3H5				M1;OUJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NVLBSnRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NWD2d25MeUiWUzDhd5NigQ>?				MnnpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	NFrvOGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	NWC3bWFOeUiWUzDhd5NigQ>?				MnTKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	NH[xXFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NV;RdJFKeUiWUzDhd5NigQ>?				NFTXflRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBQUFNvNUCgZ4VtdHN?	M1;ONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NETvOYFyUFSVIHHzd4F6				M33jSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	MonBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MlTCdWhVWyCjc4PhfS=>				MnvOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M1LIfpFJXFNiYYPzZZk>				MlKwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	M1fBPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	Mn3FdWhVWyCjc4PhfS=>				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	M2PQNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NGrpXFFyUFSVIHHzd4F6				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	MmC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	Ml3QdWhVWyCjc4PhfS=>				Mor2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NI\pPY9yUFSVIHHzd4F6				M3O5Z5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	NEfzbHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820) dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)